Ollin Biosciences Launches with Mission to Accelerate Best-in-class Therapies in Ophthalmology
Summary
Ollin Biosciences launched as a clinical-stage biopharmaceutical company focused on vision-threatening eye diseases. The company secured $100 million in initial financing from ARCH Venture Partners, Mubadala Capital, and Monograph Capital. It is advancing two bispecific antibody programs, OLN324 for wet AMD and DME and OLN102 for thyroid eye disease and Graves disease. Ollin said it will use validated biology, clinical development expertise, and data science tools to accelerate its pipeline. The company also highlighted ongoing collaboration with Innovent Biologics and VelaVigo.
Funding
Amount
$100.0M
Total raised
Date
September 17, 2025
Announcement date
Investors
ARCH Venture Partners
Lead investors
Company
ollin.bio
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected